GlassScriptPhysician profile
Robert S Wiesen
NPI 1437103678
$15,766.42
in general payments reported to CMS, 2019-2025
30 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $346 · 2021: $686 · 2022: $7,209 · 2023: $4,768 · 2024: $1,075 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Food and Beverage: $3,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Food and Beverage | $3,228.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $9,892.67 | 2022-2024 | Omvoh |
| Abbvie INC. | $1,325.09 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $766.57 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $702.42 | 2019-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $512.71 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $271.80 | 2019-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $268.10 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $263.39 | 2019-2025 | |
| Celgene Corporation | $240.87 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $230.82 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $194.76 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $172.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Boston Scientific Corporation | $120.57 | 2022 | |
| Braintree Laboratories, INC. | $104.05 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $103.78 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $76.15 | 2020-2025 | |
| Madrigal Pharmaceuticals | $53.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $50.82 | 2025 | |
| Bausch & Lomb Americas INC. | $45.55 | 2024-2025 | Envista Mx60 Iol, Envista Aspire Iol |
| Ipsen Biopharmaceuticals, INC | $39.39 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $38.99 | 2019-2021 | |
| Redhill Biopharma INC. | $28.79 | 2020-2021 | |
| Qol Medical, LLC | $28.34 | 2021-2022 | |
| Organon LLC | $27.83 | 2022-2023 | Hadlima |
| Aimmune Therapeutics, INC. | $21.90 | 2025 | Zenpep |
| Exact Sciences Corporation | $20.05 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $14.52 | 2019 | |
| Allergan, INC. | $12.65 | 2019 | |
| Shionogi INC | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wiesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.